More articles from GU

You have access
Impact of furosemide induced forced diuresis on positivity rate and physiologic radiotracer activity in patients undergoing 68Ga PSMA-11 PET/CT
Ashwin Singh Parihar, Kunal Chandekar, Swayamjeet Satapathy, Charles Marcus, Olayinka Abiodun-Ojo, Rajender Kumar, Anish Bhattacharya, Bhagwant Mittal and David Schuster

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3068;
You have access
Changes in Quantitative PSMA PET Metrics and PSA Progression-Free Survival following Initiation of Androgen Deprivation Therapy in Prostate Cancer Patients: a retrospective single-center study
Vishnu Murthy, Emmanuel Appiah-Kubi, Kathleen Nguyen, Pan Thin, Masatoshi Hotta, Andrei Gafita, Ida Sonni and Jeremie Calais

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3091;
You have access
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Heying Duan, Valentina Ferri, Pejman Ghanouni, Bruce Daniel, Jarrett Rosenberg, Negin Hatami, Guido Davidzon, Carina Mari Aparici, Alan Thong, Geoffrey Sonn, Christian Kunder and Andrei Iagaru

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3090;
You have access
Local relapse of prostate cancer after primary treatment –impact of 18F-PSMA-PET/CT on radiation oncology
Stefan A. Koerber, Ron Kröner, Katharina Dendl, Christoph Fink, Jonas Ristau, Clemens Kratochwil, Eric Winter, Uwe Haberkorn, Jürgen Debus and Frederik Giesel

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3063;
You have access
Radiomics features of PSMA-based 18F-DCFPyL PET/MRI for prediction of progression in men with high-risk primary prostate cancer undergoing neoadjuvant chemohormonal therapy
Changhee Lee, Petra Lovrec, Tyler Bradshaw, Christos Kyriakopoulos, Wei Huang, David Beebe, David Jarrard, Joshua Lang, Shane Wells and Steve Cho

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3085;
You have access
Correlation between serum PSA and PSMA targeting 18F-Florastamin PET/CT parameters in patients with prostate cancer
Sun Ha Boo, Joo Hyun O, Sonya Park, Seunggyun Ha and Ji Youl Lee

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3086;
You have access
Biochemical recurrence after 18F-DCFPyL PET guided therapy of prostate cancer oligometastases
Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei Iagaru

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3071;
You have access
Quantitative Assessment of PSMA PET Response to Androgen Deprivation in Veterans with Treatment Naïve Castration Sensitive Prostate Cancer
Nicholas Nickols, Aseem Anand, Karl Sjostrand, Gholam Berenji, Nathanael Kane, Clayton Smith, Sai Duriseti, Jeremie Calais and Matthew Rettig

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3070;
You have access
Diagnostic role of 18F-FDG PET/CT in upper urinary tract urothelial carcinoma – a rare clinicopathological entity
Kunal Chandekar, Harmandeep Singh, Rajender Kumar, Anish Bhattacharya, Bhagwant Mittal and Shrawan Kumar Singh

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3079;
You have access
Prognostic value of 99mTc-HYNIC-Octreotide scan in metastatic castrate resistant prostate cancer patients candidate for 177Lu-PSMA radioligand therapy
Ghazal Norouzi, Elahe Pirayesh and Mehrdad Tavakoli

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3078;

Main menu

User menu

Search

More articles from GU

Pages